Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Hereditary tyrosinaemia type I: a long-term study of the relationship between the urinary excretions of succinylacetone and delta-aminolevulinic acid.

Schierbeek H, Beukeveld GJ, van Faassen H, van Spronsen FJ, Bijsterveld K, Venekamp-Hoolsema EE, Wolthers BG, Smit GP.

J Inherit Metab Dis. 1993;16(6):1034-40.

PMID:
8127053
2.

Urinary succinylacetone presence and delta-aminolaevulinic acid excretion in patients with type I tyrosinaemia during treatment.

Pronicka E, Mielniczuk Z, Rowińska E, Ksiazyk J, Szczygielska-Kozak M, Wieczorek E, Kulczycka H.

Mater Med Pol. 1991 Apr-Jun;23(2):136-8.

PMID:
1842600
3.

Urinary excretion of succinylacetone and delta-aminolevulinic acid in patients with hereditary tyrosinemia.

Christensen E, Jacobsen BB, Gregersen N, Hjeds H, Pedersen JB, Brandt NJ, Baekmark UB.

Clin Chim Acta. 1981 Nov 11;116(3):331-41.

PMID:
7296896
4.

Contribution of extrahepatic tissues to biochemical abnormalities in hereditary tyrosinemia type I: study of three patients after liver transplantation.

Tuchman M, Freese DK, Sharp HL, Ramnaraine ML, Ascher N, Bloomer JR.

J Pediatr. 1987 Mar;110(3):399-403.

PMID:
3546650
5.

Liver transplantation in nine Spanish patients with tyrosinaemia type I.

Pérez-Cerdá C, Merinero B, Sanz P, Castro M, Gangoiti J, García MJ, Díaz M, Medina E, Ugarte M.

J Inherit Metab Dis. 1995;18(2):119-22. No abstract available.

PMID:
7564224
6.

Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase.

Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B.

Lancet. 1992 Oct 3;340(8823):813-7.

PMID:
1383656
7.

Tyrosinaemia type Ia without excess of urinary succinylacetone.

Biasucci G, Giuffré B, La Grutta S, Riva E.

J Inherit Metab Dis. 1993;16(6):1056-7. No abstract available.

PMID:
8127063
8.
10.

Hereditary tyrosinemia. Formation of succinylacetone-amino acid adducts.

Manabe S, Sassa S, Kappas A.

J Exp Med. 1985 Sep 1;162(3):1060-74.

11.

Persistent succinylacetone excretion after liver transplantation in a patient with hereditary tyrosinaemia type I.

Tuchman M, Freese DK, Sharp HL, Whitley CB, Ramnaraine ML, Ulstrom RA, Najarian JS, Ascher N, Buist NR, Terry AB.

J Inherit Metab Dis. 1985;8(1):21-4.

PMID:
2581063
12.

Lack of hemodynamic effects after extended heme synthesis inhibition by succinylacetone in rats.

Bourque SL, Benjamin CD, Adams MA, Nakatsu K.

J Pharmacol Exp Ther. 2010 Apr;333(1):290-6. doi: 10.1124/jpet.109.162966. Epub 2010 Jan 13.

PMID:
20071481
14.

Dietary treatment eliminates succinylacetone from the urine of a patient with tyrosinaemia type 1.

Bain MD, Purkiss P, Jones M, Bingham P, Stacey TE, Chalmers RA.

Eur J Pediatr. 1990 Jun;149(9):637-9.

PMID:
2373116
15.

Plasma succinylacetone is persistently raised after liver transplantation in tyrosinaemia type 1.

Bartlett DC, Preece MA, Holme E, Lloyd C, Newsome PN, McKiernan PJ.

J Inherit Metab Dis. 2013 Jan;36(1):15-20. doi: 10.1007/s10545-012-9482-1. Epub 2012 Mar 29.

PMID:
22456946
16.

On rat renal aminolevulinate transport and metabolism in experimental Fanconi syndrome.

Roth KS, Carter BE, Moses LC, Spencer PD.

Biochem Med Metab Biol. 1990 Dec;44(3):238-46.

PMID:
2288767
17.

Renal function in tyrosinaemia type I after liver transplantation: a long-term follow-up.

Pierik LJ, van Spronsen FJ, Bijleveld CM, van Dael CM.

J Inherit Metab Dis. 2005;28(6):871-6. Erratum in: J Inherit Metab Dis. 2006 Aug;29(4):597.

PMID:
16435179
18.

On the renal tubular damage in hereditary tyrosinemia and on the formation of succinylacetoacetate and succinylacetone.

Fällström SP, Lindblad B, Steen G.

Acta Paediatr Scand. 1981;70(3):315-20.

PMID:
7246125
20.

[Surgical and metabolic aspects of liver transplantation for tyrosinemia].

Bruneau N, St-Vil D, Luks FI, LaBerge JM, Bensoussan AL, Blanchard H.

Ann Chir. 1993;47(9):803-9. French.

PMID:
8141543

Supplemental Content

Support Center